Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer

Stopped early · Phase 3

Conditions studied: Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Adenosquamous Cell

In brief

The objective of this study is to test a clinical benefit of the addition of CP 751,871 to erlotinib therapy in patients with advanced NSCLC of non adenocarcinoma histology. The primary endpoint is Overall Survival (OS).

Key facts

Study ID

NCT00673049

Run by

Pfizer

People needed

583

Starts

2008-05-01

Expected to finish

2012-04-01

Last updated by the study team

2013-07-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Non small cell lung cancer with a primary histology of squamous cell, large cell or adenosquamous carcinoma. At least 1 measurable lesion, as defined by RECIST.

You may not qualify if…

• Primary NSCLC adenocarcinoma and its subtypes or unknown/unspecified histology.
• Prior Erlotinib therapy.
• Prior anti IGF IR based investigational therapy.

Where it is running

• Pfizer Investigational Site — Hot Springs, Arkansas, United States
• Pfizer Investigational Site — Lakeport, California, United States
• Pfizer Investigational Site — Orange, California, United States
• Pfizer Investigational Site — Orange, California, United States
• Pfizer Investigational Site — Petaluma, California, United States
• Pfizer Investigational Site — Santa Rosa, California, United States
• Pfizer Investigational Site — Thousand Oaks, California, United States
• Pfizer Investigational Site — Westlake Valley, California, United States
• Pfizer Investigational Site — Denver, Colorado, United States
• Pfizer Investigational Site — Lafayette, Colorado, United States
• Pfizer Investigational Site — Hollywood, Florida, United States
• Pfizer Investigational Site — Lake City, Florida, United States
• Pfizer Investigational Site — Lake City, Florida, United States
• Pfizer Investigational Site — Pembroke Pines, Florida, United States
• Pfizer Investigational Site — Alpharetta, Georgia, United States
• Pfizer Investigational Site — Atlanta, Georgia, United States
• Pfizer Investigational Site — Atlanta, Georgia, United States
• Pfizer Investigational Site — Atlanta, Georgia, United States
• Pfizer Investigational Site — Conyers, Georgia, United States
• Pfizer Investigational Site — Cumming, Georgia, United States
• Pfizer Investigational Site — Decatur, Georgia, United States
• Pfizer Investigational Site — Duluth, Georgia, United States
• Pfizer Investigational Site — Lake Spivey, Georgia, United States
• Pfizer Investigational Site — Lawrenceville, Georgia, United States
• Pfizer Investigational Site — Fort Smith, Arkansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.